CD274 and non-small cell lung carcinoma: Recent clinical trial studies targeting PD-L1 include avelumab and durvalumab, and the most recent follow-up results for avelumab and the positive results shown with durvalumab in NSCLC patients after radiotherapy provide a potential treatment option [116].